Resultado da Busca
Há 1 dia · Grainne O’Kane: GIANT trial in more than 70 years/ vulnerable PDAC at ASCO24 / 5‐Fluorouracil, ASCO, ASCO24, cancer, Gemcitabine plus nab-Paclitaxel (GnP),
Há 1 dia · International Society for Diseases of the Esophagus, Association for Diseases of the Esophagus
Há 1 dia · These findings highlight the potential of targeting the TGFβ/ROCK2/YAP signaling axis to mitigate fibrotic barriers and enhance drug delivery in pancreatic cancer, offering promising prospects for improving treatment outcomes in this challenging disease. Looking ahead, the implications of the study extend beyond pancreatic cancer alone.
Há 1 dia · Disitamab vedotin monotherapy, or combined therapy with toripalimab, showed promising anti-tumor activity in metastatic urothelial carcinoma. This Phase II trial aimed to evaluate the safety and efficacy of disitamab vedotin plus toripalimab as perioperative therapy in MIBC patients and the interim results presented at ASCO showed promising efficacy results with a manageable safety profile in ...
Há 7 horas · Renal cell carcinoma is the most common type of adult kidney cancer. It is responsible for approximately 85% of kidney neoplasms. Renal cell carcinoma may be clinically asymptomatic for the ...
Há 5 horas · Conquer Cancer®, the ASCO Foundation, presented the 2024 Young Investigator Awards (YIAs) funded by Vaniam Group™ and Women Leaders in Oncology® (WLO) on May 31. Both annual awards recognize ...
6 de jun. de 2024 · YANTAI, China, June 5, 2024 /PRNewswire/ — RemeGen Co., Ltd. (“RemeGen” or “the Company”) (9995.HK, SHA: 688331), a commercial-stage biotechnology company, showcased its innovation in the field of global cancer treatment at the American Society of Clinical Oncology Annual Meeting (ASCO 2024) held in Chicago from May 31-June 4, 2024, sharing major research results including its ...
